← Eichor
Study identifier: NCT07199894 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE

Condition: Nocturnal Enuresis in Children  ·  Sponsor: Mansoura University

PhasePhase 3
Planned participants120
Who can joinAll sexes, 6 Years to 18 Years
Healthy volunteersNo

About this study

The goal of this clinical trial is to compare combination of Solifenacin and MIrabegron in treatment of primary mono-symptomatic nocturnal enuresis in children. It will also learn about the safety of that combination. The main questions it aims to answer are: Does combination of Solifenacin and MIrabegron lower the number of wet nights? What medical problems do participants have when taking combination of Solifenacin and MIrabegron? Researchers will compare the combination to omegapress to see if the combination works better to treat primary mono-symptomatic nocturnal enuresis. Participants will: Take the combination or Omegapress every day for 3 months Visit the clinic once monthly for checkups and tests Keep a diary of their symptoms and the number of wet nights

This description comes directly from the study's public registry record.

Talk to the study team

Abdelhamid El Sayed Shahin, MBBCH  ·  +201005876463  ·  hameedshahin95@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Urology and Nephrology center - Mansoura UniversityAl Mansurah, EgyptRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07199894